Urogen Pharma (URGN) Competitors

$28.89 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$28.90 +0.01 (+0.03%)

As of 05/22/2026 05:36 PM Eastern

URGN vs. SRRK, IMVT, CNTA, COGT, and XENE

Should you buy Urogen Pharma stock or one of its competitors? MarketBeat compares Urogen Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Urogen Pharma include Scholar Rock (SRRK), Immunovant (IMVT), Centessa Pharmaceuticals (CNTA), Cogent Biosciences (COGT), and Xenon Pharmaceuticals (XENE). These companies are all part of the "pharmaceutical products" industry.

How does Urogen Pharma compare to Scholar Rock?

Scholar Rock (NASDAQ:SRRK) and Urogen Pharma (NASDAQ:URGN) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, profitability, dividends, earnings and media sentiment.

Scholar Rock has a net margin of 0.00% compared to Urogen Pharma's net margin of -94.83%. Urogen Pharma's return on equity of 0.00% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scholar Rock	N/A	-163.52%	-96.67%
Urogen Pharma	-94.83%	N/A	-62.85%

Urogen Pharma has higher revenue and earnings than Scholar Rock. Scholar Rock is trading at a lower price-to-earnings ratio than Urogen Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scholar Rock	N/A	N/A	-$377.94M	-$3.59	N/A
Urogen Pharma	$109.79M	12.82	-$153.49M	-$2.75	N/A

Scholar Rock has a beta of 0.7, indicating that its stock price is 30% less volatile than the broader market. Comparatively, Urogen Pharma has a beta of 1.58, indicating that its stock price is 58% more volatile than the broader market.

Scholar Rock currently has a consensus price target of $56.00, suggesting a potential upside of 16.35%. Urogen Pharma has a consensus price target of $36.67, suggesting a potential upside of 26.92%. Given Urogen Pharma's higher probable upside, analysts clearly believe Urogen Pharma is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	5 Strong Buy rating(s)	3.17
Urogen Pharma	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

91.1% of Scholar Rock shares are owned by institutional investors. Comparatively, 91.3% of Urogen Pharma shares are owned by institutional investors. 13.3% of Scholar Rock shares are owned by insiders. Comparatively, 4.7% of Urogen Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Scholar Rock had 1 more articles in the media than Urogen Pharma. MarketBeat recorded 3 mentions for Scholar Rock and 2 mentions for Urogen Pharma. Scholar Rock's average media sentiment score of 0.72 beat Urogen Pharma's score of 0.26 indicating that Scholar Rock is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Scholar Rock	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Urogen Pharma	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Urogen Pharma beats Scholar Rock on 9 of the 16 factors compared between the two stocks.

How does Urogen Pharma compare to Immunovant?

Urogen Pharma (NASDAQ:URGN) and Immunovant (NASDAQ:IMVT) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, media sentiment, valuation, dividends, risk and profitability.

Urogen Pharma currently has a consensus target price of $36.67, suggesting a potential upside of 26.92%. Immunovant has a consensus target price of $35.33, suggesting a potential upside of 3.47%. Given Urogen Pharma's stronger consensus rating and higher possible upside, equities research analysts plainly believe Urogen Pharma is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Urogen Pharma	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
Immunovant	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45

91.3% of Urogen Pharma shares are owned by institutional investors. Comparatively, 47.1% of Immunovant shares are owned by institutional investors. 4.7% of Urogen Pharma shares are owned by insiders. Comparatively, 1.8% of Immunovant shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Urogen Pharma has a beta of 1.58, indicating that its stock price is 58% more volatile than the broader market. Comparatively, Immunovant has a beta of 0.7, indicating that its stock price is 30% less volatile than the broader market.

In the previous week, Immunovant had 23 more articles in the media than Urogen Pharma. MarketBeat recorded 25 mentions for Immunovant and 2 mentions for Urogen Pharma. Immunovant's average media sentiment score of 0.36 beat Urogen Pharma's score of 0.26 indicating that Immunovant is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Urogen Pharma	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Immunovant	10 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Neutral

Urogen Pharma has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than Urogen Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Urogen Pharma	$109.79M	12.82	-$153.49M	-$2.75	N/A
Immunovant	N/A	N/A	-$413.84M	-$2.78	N/A

Immunovant has a net margin of 0.00% compared to Urogen Pharma's net margin of -94.83%. Urogen Pharma's return on equity of 0.00% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Urogen Pharma	-94.83%	N/A	-62.85%
Immunovant	N/A	-65.66%	-59.88%

Summary

Urogen Pharma beats Immunovant on 12 of the 16 factors compared between the two stocks.

How does Urogen Pharma compare to Centessa Pharmaceuticals?

Urogen Pharma (NASDAQ:URGN) and Centessa Pharmaceuticals (NASDAQ:CNTA) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, earnings, dividends, institutional ownership, media sentiment, profitability and analyst recommendations.

91.3% of Urogen Pharma shares are owned by institutional investors. Comparatively, 82.0% of Centessa Pharmaceuticals shares are owned by institutional investors. 4.7% of Urogen Pharma shares are owned by company insiders. Comparatively, 4.1% of Centessa Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Urogen Pharma has a beta of 1.58, suggesting that its share price is 58% more volatile than the broader market. Comparatively, Centessa Pharmaceuticals has a beta of 1.13, suggesting that its share price is 13% more volatile than the broader market.

In the previous week, Urogen Pharma had 2 more articles in the media than Centessa Pharmaceuticals. MarketBeat recorded 2 mentions for Urogen Pharma and 0 mentions for Centessa Pharmaceuticals. Urogen Pharma's average media sentiment score of 0.26 beat Centessa Pharmaceuticals' score of 0.00 indicating that Urogen Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
Urogen Pharma	Neutral
Centessa Pharmaceuticals	Neutral

Urogen Pharma has higher revenue and earnings than Centessa Pharmaceuticals. Centessa Pharmaceuticals is trading at a lower price-to-earnings ratio than Urogen Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Urogen Pharma	$109.79M	12.82	-$153.49M	-$2.75	N/A
Centessa Pharmaceuticals	$15M	395.46	-$197.53M	-$1.79	N/A

Centessa Pharmaceuticals has a net margin of 0.00% compared to Urogen Pharma's net margin of -94.83%. Urogen Pharma's return on equity of 0.00% beat Centessa Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Urogen Pharma	-94.83%	N/A	-62.85%
Centessa Pharmaceuticals	N/A	-60.37%	-44.17%

Urogen Pharma currently has a consensus price target of $36.67, suggesting a potential upside of 26.92%. Centessa Pharmaceuticals has a consensus price target of $40.70, suggesting a potential upside of 2.39%. Given Urogen Pharma's stronger consensus rating and higher possible upside, research analysts plainly believe Urogen Pharma is more favorable than Centessa Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Urogen Pharma	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
Centessa Pharmaceuticals	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21

Summary

Urogen Pharma beats Centessa Pharmaceuticals on 13 of the 17 factors compared between the two stocks.

How does Urogen Pharma compare to Cogent Biosciences?

Cogent Biosciences (NASDAQ:COGT) and Urogen Pharma (NASDAQ:URGN) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, valuation, institutional ownership, analyst recommendations and media sentiment.

Cogent Biosciences currently has a consensus price target of $43.73, indicating a potential upside of 33.85%. Urogen Pharma has a consensus price target of $36.67, indicating a potential upside of 26.92%. Given Cogent Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Cogent Biosciences is more favorable than Urogen Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86
Urogen Pharma	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

Cogent Biosciences has a beta of 0.37, indicating that its stock price is 63% less volatile than the broader market. Comparatively, Urogen Pharma has a beta of 1.58, indicating that its stock price is 58% more volatile than the broader market.

Urogen Pharma has higher revenue and earnings than Cogent Biosciences. Cogent Biosciences is trading at a lower price-to-earnings ratio than Urogen Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A
Urogen Pharma	$109.79M	12.82	-$153.49M	-$2.75	N/A

Cogent Biosciences has a net margin of 0.00% compared to Urogen Pharma's net margin of -94.83%. Urogen Pharma's return on equity of 0.00% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cogent Biosciences	N/A	-104.27%	-54.64%
Urogen Pharma	-94.83%	N/A	-62.85%

In the previous week, Urogen Pharma had 2 more articles in the media than Cogent Biosciences. MarketBeat recorded 2 mentions for Urogen Pharma and 0 mentions for Cogent Biosciences. Urogen Pharma's average media sentiment score of 0.26 beat Cogent Biosciences' score of 0.00 indicating that Urogen Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Cogent Biosciences	Neutral
Urogen Pharma	Neutral

91.3% of Urogen Pharma shares are owned by institutional investors. 7.3% of Cogent Biosciences shares are owned by insiders. Comparatively, 4.7% of Urogen Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Cogent Biosciences and Urogen Pharma tied by winning 8 of the 16 factors compared between the two stocks.

How does Urogen Pharma compare to Xenon Pharmaceuticals?

Xenon Pharmaceuticals (NASDAQ:XENE) and Urogen Pharma (NASDAQ:URGN) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, valuation and risk.

95.5% of Xenon Pharmaceuticals shares are owned by institutional investors. Comparatively, 91.3% of Urogen Pharma shares are owned by institutional investors. 4.1% of Xenon Pharmaceuticals shares are owned by insiders. Comparatively, 4.7% of Urogen Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Xenon Pharmaceuticals and Xenon Pharmaceuticals both had 2 articles in the media. Xenon Pharmaceuticals' average media sentiment score of 0.62 beat Urogen Pharma's score of 0.26 indicating that Xenon Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xenon Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Urogen Pharma	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Xenon Pharmaceuticals has a beta of 0.65, suggesting that its share price is 35% less volatile than the broader market. Comparatively, Urogen Pharma has a beta of 1.58, suggesting that its share price is 58% more volatile than the broader market.

Xenon Pharmaceuticals presently has a consensus target price of $77.07, suggesting a potential upside of 42.27%. Urogen Pharma has a consensus target price of $36.67, suggesting a potential upside of 26.92%. Given Xenon Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Xenon Pharmaceuticals is more favorable than Urogen Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xenon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	3.00
Urogen Pharma	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

Xenon Pharmaceuticals has a net margin of 0.00% compared to Urogen Pharma's net margin of -94.83%. Urogen Pharma's return on equity of 0.00% beat Xenon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xenon Pharmaceuticals	N/A	-49.23%	-46.42%
Urogen Pharma	-94.83%	N/A	-62.85%

Urogen Pharma has higher revenue and earnings than Xenon Pharmaceuticals. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than Urogen Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xenon Pharmaceuticals	$7.50M	698.22	-$345.91M	-$4.70	N/A
Urogen Pharma	$109.79M	12.82	-$153.49M	-$2.75	N/A

Summary

Xenon Pharmaceuticals beats Urogen Pharma on 9 of the 16 factors compared between the two stocks.

Get Urogen Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding URGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

URGN vs. The Competition

Export

Metric	Urogen Pharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.41B	$3.37B	$6.45B	$12.34B
Dividend Yield	N/A	2.26%	2.76%	5.28%
P/E Ratio	-10.51	18.74	21.22	25.65
Price / Sales	12.82	323.98	553.92	86.28
Price / Cash	N/A	125.17	43.49	56.67
Price / Book	-11.33	7.09	10.37	7.14
Net Income	-$153.49M	$24.45M	$3.57B	$335.98M
7 Day Performance	1.08%	5.45%	6.01%	3.56%
1 Month Performance	19.83%	2.43%	3.52%	2.54%
1 Year Performance	589.50%	62.98%	34.13%	35.05%

Urogen Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
URGN Urogen Pharma	3.357 of 5 stars	$28.89 flat	$36.67 +26.9%	+589.5%	$1.41B	$109.79M	N/A	200	Gap Up
SRRK Scholar Rock	2.5986 of 5 stars	$50.17 +2.0%	$56.00 +11.6%	+60.4%	$6.01B	N/A	N/A	140
IMVT Immunovant	1.7106 of 5 stars	$29.25 +2.1%	$32.44 +10.9%	+136.2%	$5.95B	N/A	N/A	120	Earnings Report Analyst Forecast
CNTA Centessa Pharmaceuticals	1.5257 of 5 stars	$39.58 -0.1%	$40.70 +2.8%	+208.9%	$5.91B	$15M	N/A	200
COGT Cogent Biosciences	2.3182 of 5 stars	$34.29 -0.7%	$43.73 +27.5%	+577.8%	$5.86B	N/A	N/A	80

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:URGN) was last updated on 5/25/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Urogen Pharma (URGN) Competitors

URGN vs. SRRK, IMVT, CNTA, COGT, and XENE

How does Urogen Pharma compare to Scholar Rock?

Summary

How does Urogen Pharma compare to Immunovant?

Summary

How does Urogen Pharma compare to Centessa Pharmaceuticals?

Summary

How does Urogen Pharma compare to Cogent Biosciences?

Summary

How does Urogen Pharma compare to Xenon Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

URGN vs. The Competition

Urogen Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Urogen Pharma (URGN) Competitors

URGN vs. SRRK, IMVT, CNTA, COGT, and XENE

How does Urogen Pharma compare to Scholar Rock?

Is SRRK or URGN more profitable?

Which has preferable valuation & earnings, SRRK or URGN?

Which has more volatility and risk, SRRK or URGN?

Do analysts prefer SRRK or URGN?

Do institutionals and insiders hold more shares of SRRK or URGN?

Does the media prefer SRRK or URGN?

Summary

How does Urogen Pharma compare to Immunovant?

Do analysts recommend URGN or IMVT?

Do insiders & institutionals have more ownership in URGN or IMVT?

Which has more risk & volatility, URGN or IMVT?

Does the media refer more to URGN or IMVT?

Which has preferable earnings and valuation, URGN or IMVT?

Is URGN or IMVT more profitable?

Summary

How does Urogen Pharma compare to Centessa Pharmaceuticals?

Do institutionals and insiders hold more shares of URGN or CNTA?

Which has more risk & volatility, URGN or CNTA?

Does the media prefer URGN or CNTA?

Which has better valuation & earnings, URGN or CNTA?

Is URGN or CNTA more profitable?

Do analysts prefer URGN or CNTA?

Summary

How does Urogen Pharma compare to Cogent Biosciences?

Do analysts recommend COGT or URGN?

Which has more volatility and risk, COGT or URGN?

Which has preferable valuation & earnings, COGT or URGN?

Is COGT or URGN more profitable?

Does the media refer more to COGT or URGN?

Do insiders and institutionals have more ownership in COGT or URGN?

Summary

How does Urogen Pharma compare to Xenon Pharmaceuticals?

Do institutionals & insiders believe in XENE or URGN?

Does the media refer more to XENE or URGN?

Which has more risk and volatility, XENE or URGN?

Do analysts rate XENE or URGN?

Is XENE or URGN more profitable?

Which has preferable valuation & earnings, XENE or URGN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

URGN vs. The Competition

Urogen Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools